Highlights

BioWa offers opportunities for partners who may benefit from a collaborative partnership. Because Potelligent^® and Complegent^® Technologies work seamlessly with conventional production and purification methods, it provides a simple plug-and-play solution to those pharmaceutical and bioscience entities seeking to optimize the potency of their therapeutic antibodies through licensing agreement.

Even our company name, BioWa, reflects our commitment. It suggests the synergistic combination of American and Japanese sensibility. “Bio”, from the West, means “life” (as biology is the study of life) and “Wa”, from the East, is most often associated with “heart” and “harmony”. Together, the name BioWa reflects an earnest objective to improve the quality of life for all.

• Incorporated: February 1, 2003
• Corporate Offices:212 Carnegie Center, Suite 101, Princeton, NJ 08540, USA
• Common Stock: $10 million USD (as of April 2005) capitalized solely by Kyowa Hakko Kirin America, Inc. (Delaware USA)
• President and CEO: Yasunori Yamaguchi, PhD